Zydus receives final approval from USFDA for Jaythari (Deflazacort) Tablets, 6 mg, 18 mg, 30 mg, and 36 mg

Ahmedabad, India, 11 April, 2025

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Jaythari® (Deflazacort) Tablets, 6 mg, 18 mg, 30 mg, and 36 mg (USRLD: Emflaza ® Tablets, 6 mg, 18 mg, 30 mg, and 36 mg).

Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Jaythari® (Deflazacort) will be produced at Doppel Farmaceutici S.r.l., Italy facility.

The group now has 424 approvals and has so far filed 492* ANDAs since the commencement of the filing process in FY 2003-04.

*(*As on 31st March, 2025.)*

PRESS RELEASE

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878